Day: October 9, 2021

— Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD —Marked Differences in Intraocular Pressure in Patients with DME Versus Wet AMD, and High 6 x 10^11 vg/eye Dose Versus Low 2 x 10^11 vg/eye DoseMarked Differences in Intraocular Pressure in Patients with DME Versus Wet AMD, and High 6 x 10^11 vg/eye Dose Versus Low 2 x 10^11 vg/eye DoseREDWOOD CITY, Calif., Oct. 09, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today is presenting data from the INFINITY clinical trial of ADVM-022 in patients with diabetic macular edema (DME) during the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting and will be presenting an encore presentation...

VANCOUVER, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) — Pender Growth Fund Inc. (TSXV: PTF) (“Pender Growth Fund” or the “Company”) announces today that it has received approval from the TSX Venture Exchange and closed the previously announced acquisition of approximately $1M in debt of GreenSpace Brands Inc. (TSXV: JTR) (“GreenSpace”). See the Company’s October 5, 2021 press release at the following link for additional details regarding the transaction: https://www.globenewswire.com/news-release/2021/10/05/2308880/0/en/Pender-Growth-Fund-Announces-Purchase-of-GreenSpace-Brands-Debt.html About Pender Growth Fund Inc.Pender Growth Fund Inc. is an investment company with the objective of achieving long-term capital appreciation for its investors. The company utilizes its small capital base and long-term horizon to invest in...